FHTX
Income statement / Annual
Last year (2025), Foghorn Therapeutics Inc's total revenue was $30.91 M,
an increase of 36.75% from the previous year.
In 2025, Foghorn Therapeutics Inc's net income was -$74.28 M.
See Foghorn Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$30.91 M |
$22.60 M |
$34.16 M |
$19.23 M |
$1.32 M |
$430.00 K |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.33 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$57.72 M
|
$1.79 M
|
$379.00 K
|
| Gross Profit |
$27.58 M
|
$22.60 M
|
$34.16 M
|
$19.23 M
|
$1.32 M
|
-$57.29 M
|
-$1.79 M
|
-$379.00 K
|
| Gross Profit Ratio |
0.89
|
1
|
1
|
1
|
1
|
-133.22
|
0
|
0
|
| Research and Development Expenses |
$85.47 M
|
$94.53 M
|
$109.69 M
|
$105.62 M
|
$80.33 M
|
$57.72 M
|
$44.36 M
|
$21.23 M
|
| General & Administrative Expenses |
$27.55 M
|
$28.36 M
|
$32.37 M
|
$30.75 M
|
$21.73 M
|
$11.25 M
|
$0.00
|
$4.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$27.55 M
|
$28.36 M
|
$32.37 M
|
$30.75 M
|
$21.73 M
|
$11.25 M
|
$4.93 M
|
$4.82 M
|
| Other Expenses |
-$3.33 M
|
$2.40 M
|
$0.00
|
$0.00
|
$0.00
|
-$57.72 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$109.68 M
|
$125.29 M
|
$142.06 M
|
$136.37 M
|
$102.05 M
|
$11.25 M
|
$49.29 M
|
$26.05 M
|
| Cost And Expenses |
$113.02 M
|
$125.29 M
|
$142.06 M
|
$136.37 M
|
$102.05 M
|
$68.96 M
|
$51.08 M
|
$26.05 M
|
| Interest Income |
$8.75 M
|
$11.90 M
|
$10.88 M
|
$5.68 M
|
$59.00 K
|
$1.00 M
|
$495.00 K
|
$113.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.91 M
|
$979.00 K
|
$540.00 K
|
$371.00 K
|
| Depreciation & Amortization |
$3.33 M
|
$3.12 M
|
$3.45 M
|
$3.32 M
|
$3.23 M
|
$1.33 M
|
$1.79 M
|
$379.00 K
|
| EBITDA |
-$78.78 M |
-$97.17 M |
-$104.46 M |
-$113.82 M |
-$96.19 M |
-$67.20 M |
-$48.80 M |
-$25.59 M |
| EBITDA Ratio |
-2.55
|
-4.3
|
-3.06
|
-5.92
|
-72.92
|
-156.29
|
0
|
0
|
| Operating Income Ratio |
-2.66
|
-4.54
|
-3.16
|
-6.09
|
-76.37
|
-159.37
|
0
|
0
|
| Total Other Income/Expenses Net |
$7.82 M
|
$16.06 M
|
$13.71 M
|
$8.26 M
|
-$586.00 K
|
-$269.00 K
|
-$44.00 K
|
-$288.00 K
|
| Income Before Tax |
-$74.28 M
|
-$86.62 M
|
-$94.20 M
|
-$108.88 M
|
-$101.32 M
|
-$68.80 M
|
-$51.13 M
|
-$26.34 M
|
| Income Before Tax Ratio |
-2.4
|
-3.83
|
-2.76
|
-5.66
|
-76.82
|
-160
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$4.23 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$83.00 K
|
| Net Income |
-$74.28 M
|
-$86.62 M
|
-$98.43 M
|
-$108.88 M
|
-$101.32 M
|
-$68.80 M
|
-$51.13 M
|
-$26.34 M
|
| Net Income Ratio |
-2.4
|
-3.83
|
-2.88
|
-5.66
|
-76.82
|
-160
|
0
|
0
|
| EPS |
-1.18 |
-1.58 |
-2.34 |
-2.62 |
-2.78 |
-1.9 |
-1.4 |
-1.34 |
| EPS Diluted |
-1.18 |
-1.58 |
-2.34 |
-2.62 |
-2.78 |
-1.9 |
-1.4 |
-1.34 |
| Weighted Average Shares Out |
$62.98 M
|
$54.90 M
|
$41.97 M
|
$41.59 M
|
$37.17 M
|
$36.79 M
|
$36.82 M
|
$19.63 M
|
| Weighted Average Shares Out Diluted |
$62.98 M
|
$54.90 M
|
$41.97 M
|
$41.59 M
|
$37.17 M
|
$36.79 M
|
$36.82 M
|
$19.63 M
|
| Link |
|
|
|
|
|
|
|
|
